Guselkumab for moderate-to-severe ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests a drug called Guselkumab (already approved for other conditions) for treating moderate to severe ulcerative colitis. It aims to see how safe and effective the drug is in real-world patients who have not had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have moderate to severe ulcerative colitis (confirmed by a doctor).
- You must have tried at least one standard treatment (like mesalamine, steroids, or immunosuppressants) that didn't work or caused side effects.
- You cannot have other bowel diseases like Crohn's, intestinal infections, or a history of severe allergic reaction to monoclonal antibodies.
- You cannot be pregnant or breastfeeding, or have serious infections, cancer, or other autoimmune diseases that could affect the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medication called Guselkumab can help people with moderate to severe Crohn's disease. It uses a special ultrasound to see how the bowel responds to treatment.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study looks at how well guselkumab works for people with moderate to severe Crohn's disease or ulcerative colitis when used as part of regular treatment. It gathers information from real patients to see how the drug performs outside of a research setting.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
This study tracks how well guselkumab (a biologic medication that blocks IL-23, a protein that drives inflammation) works for moderate-to-severe ulcerative colitis or Crohn's disease in everyday clinical practice. Researchers want to understand long-term benefits and safety in real patients.
Hear when a new Ulcerative Colitis (Disorder) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.